HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer to Drive Cardiac Technology Commercialization

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care through actionable cardiac insights, announced the appointment of Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. In the newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia assessment, heart attack detection indication and a 12-lead ECG extended wear patch monitor, while expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption.

The appointment comes at a critical juncture for HeartBeam as the company commercializes its FDA-cleared technology. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.

HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025. The company’s cleared indications for use are detailed at https://www.heartbeam.com/indications. This regulatory clearance represents a significant milestone that enables the company to bring its innovative cardiac monitoring solutions to market. The technology addresses a critical need in cardiac care by allowing for continuous monitoring outside traditional medical settings, potentially enabling earlier detection of cardiac events and more proactive management of heart conditions.

The commercial leadership provided by Humbarger will be essential for navigating the complex healthcare landscape and establishing HeartBeam’s technology as a standard of care in cardiac monitoring. His role will involve coordinating the limited launch of the HeartBeam System while working to validate the technology’s real-world performance through partnerships with cardiology providers. This strategic approach aims to build clinical evidence and establish reference sites that can demonstrate the technology’s value proposition to the broader medical community.

The appointment signals HeartBeam’s transition from a development-stage company to one focused on commercialization and market adoption. As the company prepares to bring its portable cardiac monitoring technology to patients and healthcare providers, the creation of the chief commercial officer position reflects the strategic importance of commercial execution in realizing the potential of HeartBeam’s innovative approach to cardiac care. The technology’s ability to provide 12-lead ECG monitoring outside medical facilities represents a paradigm shift in how cardiac conditions can be detected and managed, potentially improving outcomes for patients with heart disease.